ライフサイエンスコーパス: thrombose

1 els), and 1.9% were in class IV (all vessels thrombosed).

2 the enlarged vein, causing the hemorrhoid to thrombose.

3 sease rarely requires surgery unless acutely thrombosed.

4 ate line, cause rectal pain when engorged or thrombosed.

5 2019 infection has been high rates of venous thromboses.

6 ability to inhibit both venous and arterial thromboses.

7 ved to influence the development of arterial thromboses.

8 ology of rejection characterized by vascular thromboses.

9 elet reactivity with a resulting increase in thromboses.

10 the cost of an increased risk of late stent thromboses.

11 o 0.95) and 0.76 (0.73 to 0.79) for arterial thromboses.

12 e of insulin resistance; there were no graft thromboses.

13 increased the risk of AMI, but not the other thromboses.

14 o 0.99) and 0.72 (0.70 to 0.75) for arterial thromboses.

15 ents with rapidly progressive multiple organ thromboses.

16 n morbidity and mortality, mainly because of thromboses.

17 ary embolism, atrial arrhythmias, and venous thromboses.

18 had intracerebral hemorrhage; 8 had non-CVST thromboses.

19 Only 4 patients died of thromboses.

20 ment similar to more proximal or symptomatic thromboses.

21 oss on the machine or postoperative vascular thromboses.

22 urring significantly earlier than peripheral thromboses.

23 yocardial infarction in analyses of arterial thromboses.

24 riant received transfusions, and 2 developed thromboses.

25 ther conditions associated with pathological thromboses.

26 rovascular aneurysms, or arterial and venous thromboses.

27 atment with heparin resulting in paradoxical thromboses.

28 s of heart disease are at increased risk for thromboses.

29 body blood vessels in the treated area were thrombosed 1 day after PDT.

30 urred in 8 pts (23.5%): 4 bleeding, 3 portal thromboses (1 complete, 2 partial), and 1 sepsis.

31 the fish oil group, there were half as many thromboses (1.71 vs 3.41 per 1000 access-days; IRR, 0.50

32 perior in the prevention of catheter-related thromboses (13 [3%] vs 34 [7%]; 0.38, 0.20-0.71, p=0.002

33 tenoses, one dissection), 185 in the EIA (17 thromboses, 167 stenoses, one dissection), one in the co

34 ases (57%): 10 venous thromboses, 3 arterial thromboses, 2 combined arterial and venous thrombosis, 2

35 did not reduce the rate of catheter-related thromboses (24 [6%] vs 24 [6%]; relative risk 0.99, 95%

36 FvQ/Q mice formed occlusive thromboses 27+/-3 minutes (n=7) after the onset of injur

37 Thirty-four major thromboses (3 fatal) and 14 major hemorrhages (none fata

38 ke (2.44 [1.04-5.75], p = 0.04) and arterial thromboses (3.49 [0.97-12.54], p = 0.05).

39 was compromised in 20 cases (57%): 10 venous thromboses, 3 arterial thromboses, 2 combined arterial a

40 pulmonary embolisms (42.2%), and deep venous thromboses (34.5%).

41 A clinically significant HAC (4 thromboses, 35 HACs requiring IVI) was found in 2.9% (n

42 imultaneous patients had more renal vascular thromboses (4.4% vs 1.3% tx alone, 0% pre; P = 0.04).

43 intimal dissections, 11 pseudoaneurysms, 17 thromboses, 4 carotid cavernous fistulas, and 1 transect

44 arrythmias (6.44, 4.17 to 9.96), and venous thromboses (5.43, 3.27 to 9.01).

45 , because of a higher proportion of arterial thromboses (6.2% vs 3.7%; P = .015).

46 In those with pulmonary arterial thromboses, 93% were identified incidentally on first sc

47 A risk-benefit analysis found 3 fewer stent thromboses (95% CI: 2 to 5) and 6 fewer MIs (95% CI: 2 t

48 thromboses after ChAdOx1-S, and for arterial thromboses after both vaccines.

49 vents were higher at younger ages for venous thromboses after ChAdOx1-S, and for arterial thromboses

50 rombocytopenia and major arterial and venous thromboses after COVID-19 vaccination.

51 s and venules in the subcutaneous layer were thrombosed and the overlying tissue was infarcted.

52 n England, there were 260 279 first arterial thromboses and 59 421 first VTEs during 41.6 million per

53 his was accompanied by more pulmonary artery thromboses and adherent hMSCs found on explanted oxygena

54 ts to proximal pulmonary arterial aneurysms, thromboses and calcification; to truncal valve stenosis

55 ischemic stroke comprise the major arterial thromboses and deep-vein thrombosis and pulmonary emboli

56 Reports of widespread thromboses and disseminated intravascular coagulation (D

57 r mediated pathways leading to microvascular thromboses and endothelial activation appear to play an

58 disorders featuring anticoagulant-refractory thromboses and intermittent thrombocytopenia that were a

59 A combined endpoint of thromboses and major bleeding showed no difference betwe

60 ies are at risk for major abdominal vascular thromboses and organ infarction.

61 symptoms to life-threatening events such as thromboses and strokes.

62 Furthermore, many isolated distal deep vein thromboses and subsegmental pulmonary emboli are identif

63 d ratios comparing the incidence of arterial thromboses and venous thromboembolic events (VTEs) after

64 ole-population increases in risk of arterial thromboses and VTEs 49 weeks after COVID-19 diagnosis we

65 wasaki disease patients with coronary artery thromboses and/or myocardial infarctions).

66 a single injection of 1,000 units, initially thrombosed, and recurred.

67 to 1.05) and 0.58 (0.53 to 0.63) for venous thromboses, and 0.90 (0.86 to 0.95) and 0.76 (0.73 to 0.

68 to 0.88) and 0.57 (0.53 to 0.62) for venous thromboses, and 0.94 (0.90 to 0.99) and 0.72 (0.70 to 0.

69 7%) were non-catheter-associated deep venous thromboses, and 9 (0.6%) were pulmonary emboli.

70 ythropoiesis and granulopoiesis, more venous thromboses, and a higher rate of polycythaemic transform

71 Thromboses are a serious complication in patients with s

72 Arterial and venous thromboses are classically considered distinct disease s

73 but catheter occlusions and catheter-related thromboses are common complications that can result from

74 treatment of central venus catheter-related thromboses are critical in the treatment of patients req

75 Thromboses are detected frequently around the time of on

76 Other thromboses are found on non-ruptured but inflamed plaque

77 Arterial and venous thromboses are the most significant complications in pat

78 Catheter-related thromboses are usually diagnosed by Doppler ultrasonogra

79 Gender differences in vascular thromboses are well known, and there is evidence that pl

80 Ten thrombosed arteries were randomly assigned to receive ea

81 thrombocytopenic purpura and other arterial thromboses associated with compromised VWF proteolysis.

82 Nine en bloc kidneys thrombosed at a mean of 4.2 days posttransplantation.

83 ring revision of TIPS with one to five prior thromboses at 1 day to 1 year after initial TIPS formati

84 nted with Fv+/+ bone marrow formed occlusive thromboses at 35+/-5 minutes (n=7, P<0.05 compared with

85 AMTS-13 activity, and VWF-rich microvascular thromboses at autopsy.

86 Five patients (33%) developed venous thromboses at the central catheter tip.

87 l external iliac arteries of 15 canines were thrombosed before mechanical thrombolysis.

88 We found distorted, degenerating, or thrombosed blood vessels within the center of more than

89 Vascular thromboses, bowel perforation, septicemia, and retranspl

90 he 20 pancreas grafts, 15 are functioning, 3 thrombosed, but 2 of those patients underwent immediate

91 prevent CVC infections and catheter-related thromboses, but confirmatory studies and cost-effectiven

92 es of the popliteal artery and the number of thrombosed calf veins was investigated.

93 Catheter-related thromboses can lead to catheter infection, pulmonary emb

94 Failure to detect and treat thromboses can result in mesenteric ischemia, chronic ca

95 he manipulation of a Swan Ganz catheter in a thrombosed central vein, resulted in pulmonary emboli th

96 and malapposed struts were more frequent in thrombosed compared with nonthrombosed regions (ratio of

97 axial malapposition distance, was greater in thrombosed compared with nonthrombosed segments.

98 inding in human VCA, consisting of capillary thromboses (CT) in the upper dermis.

99 In some rare cases, cerebral venous sinus thromboses (CVST) have been reported as a severe side ef

100 No inhibitor development, thromboses, deaths, or persistent changes in liver-funct

101 An uncomplicated deep vein thromboses developed in one patient with a history of re

102 Thromboses developed in six of 240 flaps (2.5%): 4 were

103 e considered as an alternative treatment for thrombosed dialysis fistulas.

104 sis patients (8 males and 4 females) with 14 thrombosed distal forearm Brescia-Cimino radiocephalic f

105 Thrombosed dural sinuses were found in 24/31 (77.4%) cas

106 mboli (PE) in cancer patients with deep vein thromboses (DVT) was reviewed to identify indications, p

107 The primary outcome was deep vein thromboses (DVTs) averted.

108 enous (21%), and five (7%) systemic arterial thromboses/end-organ embolic complications.

109 ncrease the risk that recently-placed stents thrombose, especially when surgery is performed early af

110 mia should undergo ultrasonography to detect thromboses even if the physical examination is normal.

111 to pharmacological triggering, plaques that thrombosed exhibited significantly higher CLIO-CyAm7 acc

112 lot evacuation within 72 hours of onset of a thrombosed external hemorrhoid is associated with decrea

113 p, leg thrombi were only 50% detectable, the thrombosed femoral area had relative counts of 118%+/-17

114 tectable, mean (+/-SD) relative count in the thrombosed femoral area was 186% (+/-30%) of the contral

115 only 75% detectable, relative counts in the thrombosed femoral areas decreased to 125% (+/-20%), and

116 chnical and clinical success was found in 12 thrombosed fistulas.

117 h late portal vein or vena caval stenoses or thromboses from a cohort of 524 grafts with survival gre

118 may permit salvage or timely removal of the thrombosed graft.

119 Thrombosed grafts were treated successfully in 1,123 of

120 Two patients with symptoms of in situ thromboses had a higher percentage of adherent cells com

121 One participant had grade 1 thrombosed haemorrhoids (classified as a thromboembolic

122 imilarly successful in the recanalization of thrombosed hemodialysis access grafts and achieved compa

123 122 randomly chosen patients with synthetic, thrombosed hemodialysis access grafts from multiple cent

124 The PTD is safe and effective for treating thrombosed hemodialysis access grafts.

125 ld be adopted as the treatment of choice for thrombosed hemodialysis access grafts.

126 20 adult patients with recently (</=14 days) thrombosed hemodialysis grafts.

127 ocytopenia (HIT) develop clinically apparent thromboses (HITT) remains uncertain.

128 such as haemodynamic compromise, infections, thromboses, impaired growth and kidney failure.

129 The main PV (MPV) was completely thrombosed in 17 of 44 (39%) patients; near complete (>9

130 among patients without thrombosis; among 40 thromboses in 40 patients who did not undergo transplant

131 and comparable between groups, with no stent thromboses in any group at 6 months.

132 rent CAPS characterized by multiple arterial thromboses in large and small vessels despite maximal an

133 ion in symptomatic catheter-related or other thromboses in patients with cancer and therefore we shou

134 common and distinct features of portal vein thromboses in patients without liver tumors, with and wi

135 population there were 22 (16.5%) episodes of thromboses in the fondaparinux group and 13 (21.4%) in t

136 om 6 months to 3 years there were more stent thromboses in the Taxus group (hazard ratio 0.19 [95% co

137 e confirmed in 66 patients; an additional 36 thromboses in unique devices were suspected.

138 Thromboses in unusual locations after the Coronavirus Di

139 Other venous thromboses include catheter- and circuit-associated in p

140 Risk factors for catheter-related thromboses include previous catheter infections, malposi

141 Prevention of catheter-related thromboses includes proper positioning of the CVC and pr

142 ), pulmonary embolism (n = 32), other venous thromboses (including deep vein thrombosis) (n = 42), an

143 Twenty-two (52%) had major vascular thromboses, including those in the inferior vena cava (n

144 The blood flow inside a tube with multi-thromboses is mathematically investigated.

145 nt is difficult and the complications of the thrombosed IVC may compromise life.

146 .9-27.4 kg) with end-stage renal disease and thrombosed IVCs were reviewed.

147 The non-thrombosed lesion that most resembles the acute plaque r

148 necrotic core prolapse was more frequent in thrombosed lesions compared with patent lesions (70% vs.

149 Thromboses limited to infrapopliteal leg deep veins (iso

150 at post-TPIAT thrombocytosis and portal vein thromboses may be linked to the islet infusion inflammat

151 enous thrombosis had more intracranial veins thrombosed (median three, IQR 2-4) than non-VITT patient

152 hemobilia due to the rupture of a partially thrombosed mycotic aneurysm into the biliary tree.

153 ocardial infarction (n = 34), other arterial thromboses (n = 26), pulmonary embolism (n = 32), other

154 mechanical thrombolysis for the treatment of thrombosed native arteriovenous fistula.

155 ble, and safe procedure for the treatment of thrombosed native arteriovenous fistula.

156 s (8 FC and 2 placebo) exhibited 12 possible thromboses; none were clearly related to FC.

157 Only 4 of 27 (14.8%) of portal vein thromboses occurred at platelet counts 500 x 109/L.

158 No deaths, malignancies, or thromboses occurred during the trial.

159 Stent thromboses occurred in 1 patient assigned to placebo <24

160 Two maternal valve thromboses occurred.

161 urred in 12.2% of patients, with portal vein thromboses occurring significantly earlier than peripher

162 win sister, who was diagnosed with extensive thromboses of the inferior vena cava, portal vein, and h

163 s, 3 had pulmonary embolism, and 4 had other thromboses; of these patients, 6 died.

164 vents per 100 patient-years) compared with 2 thromboses on eculizumab (0.8 events per 100 patient-yea

165 These studies demonstrate markedly increased thromboses on stents with blood isolated from HPA Tg mic

166 fold group had definite or probable scaffold thromboses (one definite acute, one definite sub-acute,

167 ntitia causing saccular aneurysms, which can thrombose or rupture.

168 neurysms may erroneously be considered to be thrombosed or be mistaken for other common lesions such

169 -risk groups such as those with prior venous thromboses or coexistent defects of anticoagulation and

170 32-65 years; mean age, 42 years), abdominal thromboses or ischemic events were detected at CT.

171 Venous thrombotic events (deep venous thromboses or pulmonary emboli) were documented and conf

172 with an mRNA COVID-19 vaccine developed new thromboses or relevant increase in anti-PF4/heparin IgG

173 demia, diabetes, initial ulcer width >20 mm, thrombosed PAU, and associated saccular aneurysm were as

174 nhanced CT revealed no recanalization of the thrombosed PAVM.

175 In thrombosed plaques, nanoparticles accumulated preferenti

176 ithin 2 weeks of function), one child with a thrombosed polar artery had a focal defect.

177 MVT replaces the liver and the thrombosed portomesenteric system.

178 factors [HRF] (multiple arteriovenous access thromboses, prior deep vein thrombosis, prior allograft

179 Obstructive thrombosed prosthetic heart valve (OTPHV) is a serious c

180 In cases where a chronically thrombosed PV has become obliterated, we developed PV re

181 Portal vein thromboses (PVTs) are common in patients with cirrhosis

182 arotid arteries of ApoE(-/-), HPS3(+/+) mice thrombosed rapidly after FeCl(3) injury, but ApoE(-/-),

183 s risk factors in patients with a history of thromboses; red cell binding sites on endothelial cells

184 asis, but its effects across the spectrum of thromboses remain poorly understood.

185 een questions if these small or asymptomatic thromboses require anticoagulation management similar to

186 The existence of these multiple thromboses restricts the blood flow in this tube and the

187 des fusiform and saccular aneurysms that can thrombose, SA/C vasculitis likely causes the transition

188 2 combined arterial and venous thrombosis, 2 thromboses secondary to allograft pancreatitis, and 3 ca

189 of gamma counts from the femoral area on the thrombosed side was compared with the contralateral side

190 cluded vessels required puncture through the thrombosed sites using a stiff wire or transseptal needl

191 In one patient, the partially thrombosed splenic artery was opened at the tail of the

192 tiple vessel-related complications including thromboses, stenoses, occlusions, and aneurysms.

193 There were no instances of graft vascular thromboses/stenoses/leaks (0%).

194 Besides CVST, splanchnic vein thromboses (SVT) and other thromboembolic events have be

195 diagnosis declines more rapidly for arterial thromboses than VTEs.

196 view of CT scans revealed more grade 1 and 2 thromboses than were initially reported.

197 and bind platelets, forming microvasculature thromboses that cause ischemic organ injury (eg, myocard

198 atient with a history of recurrent deep vein thromboses that had no adverse effect on her outcome.

199 ght heparin was instituted to prevent venous thromboses, the combination regimen was well tolerated.

200 hepatic artery stenoses, six hepatic artery thromboses, two hepatic artery pseudoaneurysms, two sple

201 , are biocompatible, and show intact, though thrombosed, vasculature.

202 l sinuses were found in 24/31 (77.4%) cases, thrombosed veins in 7/31 (22.6%) cases, no lesions withi

203 The luminal diameter of thrombosed veins was equal to or larger than that of a c

204 ategies have been used to restore patency of thrombosed veins, including open surgical thrombectomy,

205 In patients with 1 and/or 2 thrombosed veins, the mean PI was 6.03+/-0.54 on the sid

206 Inpatients with 3 and/or 4 thrombosed veins, the mean PI was 8.05+/-0.61 on the sid

207 ombus thickness was significantly greater in thrombosed versus patent lesions.

208 Those patients with multiple thrombosed vessels (class III and above) should be stron

209 ucer may be a method of recanalizing acutely thrombosed vessels if the impulses are applied only when

210 The endothelial lining of thrombosed vessels typically lacked evidence of cytokine

211 lts, 51.9% of patients fell into class I (no thrombosed vessels), 21.7% were in class II (one occlude

212 rombosis), 24.5% were in class III (multiple thrombosed vessels), and 1.9% were in class IV (all vess

213 3-4 pancreatitis, central neurotoxicity, and thromboses was 12%, 4%, and 6%, respectively, and not as

214 with synthetic forearm loop shunts that were thrombosed were randomly assigned to undergo pharmacomec

215 Stent thromboses were also assessed.

216 Portal vein thromboses were associated with infused islet volumes an

217 A total of 72 pump thromboses were confirmed in 66 patients; an additional

218 Main sites of thromboses were deep veins of the extremities (10 of 23;

219 Breakthrough thromboses were rare, although anticoagulant prophylaxis

220 uary 2008 and September 2013, 26 (0.61%) THV thromboses were reported out of 4266 patients undergoing

221 No late stent thromboses were seen in any treated group despite clopid

222 The multiple thromboses with increasing heights are evident in stream

223 passing treatment of any unknown concomitant thromboses with only low risk for hemorrhage.

224 symptoms, vasomotor symptoms, and deep vein thromboses with tamoxifen.

225 There were no deep vein thromboses, with 1 superfificial venous thrombosis in ea